Skip to content
CA.gov logo in white
  • Grants Management System
  • CIRM Hub Portal
  • Contact
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Strategic Goals
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Strategic Goals
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingGene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingStudy to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis

Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingExtracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingA Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingIntra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingFeasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingA Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

RAPA-501 Therapy of ALS Expanded Access Protocol

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingRAPA-501 Therapy of ALS Expanded Access Protocol

Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingHumanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia
  • Go to the previous page
  • 1
  • …
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • …
  • 32
  • Go to the next page
  • Careers
  • Administrative & Financials
  • Accessibility

Subscribe to Receive CIRM News

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox. 

Sign Up
Facebook-f X-twitter Instagram Linkedin Youtube
  • Privacy Policy
  • ©2025 California Institute for Regenerative Medicine
  • Media Guidelines
  • Contact Us